Xavier is the Head of Clinical Development of Ventus Therapeutics. He brings to Ventus more than 25 years of industry and academic experience in immunology and autoimmunity.
Prior to Ventus, Xavier served as head of clinical development at multiple biotech companies, including Tr1X, Strongbridge Biopharma, and Boston Pharmaceuticals, where he was responsible for all aspects of clinical development, from IND submission to BLA/NDA filings. His experience spans several therapeutic modalities, including small molecules, biologics, and gene and cell therapy. Prior to his tenure in biotech, Xavier served in positions of increasing responsibility in global immunology clinical development at BMS, GSK, and Novo Nordisk. During his academic career, Xavier discovered cadherin-11 to be the molecule responsible for maintaining synovial architecture and its overexpression in rheumatoid arthritis while at Brigham and Women’s Hospital. He also spent over six years at the NIH researching the role of FoxP3 regulatory T cells in systemic autoimmune diseases.
Xavier holds an M.D. from the School of Medicine of the National Autonomous University of Mexico and is a board-certified rheumatologist.
